Fluoroquinolones are antimicrobial agents used frequently around the world. Fluoroquinolone-resistant and multidrug-resistant gram-negative bacterial pathogens are emerging infectious disease agents of worldwide concern. The long-term goals of the Zechiedrich laboratory are to determine how gram-negative bacteria respond to and develop resistance to antimicrobial agents and to use this knowledge to improve diagnosis of antibiotic-resistant bacterial infections, to prolong the usefulness of current drugs and to aid in the design of new therapeutic protocols. In the previous funding periods, we built a database that combines patient, hospital, and microbiological data from bacterial isolates that we have collected since 1999. Utilizing this database, we are working toward repurposing an off-patent antifungal drug as an antimicrobial agent with excellent activity against gram-negative pathogens. To discover new fluoroquinolone resistance mechanisms, we used a novel genome pooling, sequencing, and SNP analysis approach. In addition to uncovering the well- known gyrA target gene SNP, we discovered three novel SNPs that were present in every fluoroquinolone- resistant isolate in our collection. We also found 35 novel SNPs associated with a fluoroquinolone susceptible phenotype and 287 SNPs associated with various additional antimicrobial resistance phenotypes. The goals of this competing renewal proposal are to determine how these genetic variants affect antibiotic resistance and to test the predictive power of these SNPs for reporting antibiotic resistance phenotypes. Success of this latter goal could be used in a rapid genome-based diagnostic assay of antibiotic resistance. Our team, at Baylor College of Medicine in the Texas Medical Center in Houston, Texas, is composed of molecular microbiologist, Zechiedrich (P.I.), physician scientist, Hamill (co-I), genomics expert, Sucgang (co-I), computational biologist, Barth (co-I), and crystallographer, Lee (co-I). Together we will achieve these goals with the following specific aims: 1. Determine how newly discovered SNPs affect antibiotic resistance;2. Identify and characterize genetic alterations associated with fluoroquinolone resistance and additional specific antibiotic resistance phenotypes;and 3. Test the diagnostic power of SNP detection as a reporter of antibiotic resistance.

Public Health Relevance

People are dying because physicians are forced to give them antibiotics before it is known whether or not their infections are resistant to those antibiotics. Results from the proposed work will allow physicians to have a new way to diagnose drug-resistant infections and use only those antibiotics that will work for a specific patient's infectin, which will save lives as well as save our country the billions of dollars in healthcare costs when the wrong antibiotic is given.

National Institute of Health (NIH)
High Priority, Short Term Project Award (R56)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Korpela, Jukka K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Schools of Medicine
United States
Zip Code